GlaxoSmithKline Stock Price Prediction

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

GlaxoSmithKline PLC stock price prediction is an act of determining the future value of GlaxoSmithKline PLC shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of GlaxoSmithKline PLC stock future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with GlaxoSmithKline PLC, which may create opportunities for some arbitrage if properly timed. Please check GlaxoSmithKline PLC Basic Forecasting Models to cross-verify your projections.

Search Stock Price Prediction

The GlaxoSmithKline stock price prediction module also provides an analysis of price elasticity to changes in media outlook on GlaxoSmithKline PLC over a specific investment horizon. Using GlaxoSmithKline PLC hype-based prediction, you can estimate the value of GlaxoSmithKline PLC from the perspective of GlaxoSmithKline PLC response to recently generated media hype and the effects of current headlines on its competitors. GlaxoSmithKline PLC PPandE Turnover is increasing as compared to previous years. The last year's value of PPandE Turnover was reported at 3.15. The current Accounts Payable Turnover is estimated to increase to 10.13, while Cash and Equivalents Turnover is estimated to decrease to 6.55.
Estimates (6)
LowProjected EPSHigh
LowEstimated ValueHigh
LowReal ValueHigh
Consensus (11)
LowTarget PriceHigh

GlaxoSmithKline PLC After-Hype Price Density Analysis

 Next price density 
      Expected price to next headline 

GlaxoSmithKline PLC Estimiated After-Hype Price Volatility

Current Value
6th of June 2020
After-hype Price
GlaxoSmithKline PLC is very steady asset. Analysis and calculation of next after-hype price of GlaxoSmithKline PLC is based on 3 months time horizon.

GlaxoSmithKline PLC Stock Price Prediction Analysis

Daily Expected returnPeriod VolatilityHype elasticityRelated hype elasticityAverage news densityRelated news densityNext Expected Hype
 0.08  3.07  0.02   0.02  10 Events / Month5 Events / MonthIn about 10 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility

GlaxoSmithKline PLC Hype Timeline

On the 6th of June GlaxoSmithKline PLC is traded for 41.70. The entity has historical hype elasticity of 0.02 and average elasticity to hype of competition of -0.02. GlaxoSmithKline PLC is estimated to increase in value after the next headline with price going to jump to 41.72. The average volatility of media hype impact on the company stock price is about 1535.0%. The price escalation on the next news is projected to be 0.05% where as daily expected return is currently at 0.08%. The volatility of related hype on GlaxoSmithKline PLC is about 1088.65% with expected price after next announcement by competition of 41.68. The company reported last year revenue of 40.01 B. Total Income to common stockholders was 2.46 B with profit before taxes, overhead, and interest of 21.11 B. Considering 30-days investment horizon, the next estimated press release will be in about 10 days.
Please check GlaxoSmithKline PLC Basic Forecasting Models to cross-verify your projections.

GlaxoSmithKline PLC Related Hype Analysis

At Risk
Astrazeneca PLC 0.92 9 per month 3.07  0.06  5.44 (4.82)  17.39 
Bristol Myers Squibb 0.10 8 per month 2.55 (0.011)  4.25 (4.39)  12.95 
GlaxoSmithKline PLC 0.20 10 per month 3.41 (0.0136)  4.97 (4.47)  16.42 
Johnson Johnson 0.50 8 per month 2.69  0.0205  7.08 (5.64)  14.74 
Eli Lilly And(0.15) 9 per month 2.86  0.0497  7.73 (6.99)  18.71 
Merck Company(0.96) 10 per month 3.02 (0.0029)  5.32 (5.46)  13.75 
Novartis AG(0.03) 8 per month 2.75 (0.0137)  4.53 (4.16)  15.61 
Gilead Sciences(2.26) 9 per month 3.39  0.0072  6.16 (5.81)  14.89 
Grifols S A(0.54) 9 per month 0.00 (0.05)  5.79 (4.97)  21.22 
GW Pharmaceuticals Plc(0.60) 9 per month 4.31  0.07  7.38 (6.90)  21.85 

Additional Predictive Modules

About GlaxoSmithKline PLC Predictive Indicators

The successful prediction of GlaxoSmithKline PLC stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as GlaxoSmithKline PLC, already reflect all publically available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'text-book' version of this hypothesis and continually tries to find mispriced stocks to increase returns on his or her portfolios. We use internally-developed statistical techniques to arrive at the intrinsic value of BlackBerry Limited based on analysis of GlaxoSmithKline PLC hews, social hype, and general headline patterns together with widely used predictive technical indicators. We also calculate exposure to GlaxoSmithKline PLC's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to GlaxoSmithKline PLC's related companies.
 2017 2019 2020 (projected)
Long Term Debt to Equity4.652.072.7
Interest Coverage5.68146.89158.48
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 99437 people.

Contributor Headline

Latest Perspective on GlaxoSmithKline PLC

Please check GlaxoSmithKline PLC Basic Forecasting Models to cross-verify your projections. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page